| 000 | 01717 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515074406.0 | ||
| 264 | 0 | _c20070914 | |
| 008 | 200709s 0 0 eng d | ||
| 022 | _a0300-9475 | ||
| 024 | 7 |
_a10.1111/j.1365-3083.2007.01981.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPérez, O | |
| 245 | 0 | 0 |
_aNew vaccines require potent adjuvants like AFPL1 and AFCo1. _h[electronic resource] |
| 260 |
_bScandinavian journal of immunology _c |
||
| 300 |
_a271-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aDose-Response Relationship, Immunologic |
| 650 | 0 | 4 | _aLiposomes |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMeningitis, Meningococcal _ximmunology |
| 650 | 0 | 4 |
_aMeningococcal Vaccines _xadministration & dosage |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 |
_aNeisseria meningitidis, Serogroup B _ximmunology |
| 650 | 0 | 4 |
_aProteolipids _xadministration & dosage |
| 700 | 1 | _aLastre, M | |
| 700 | 1 | _aCabrera, O | |
| 700 | 1 | _adel Campo, J | |
| 700 | 1 | _aBracho, G | |
| 700 | 1 | _aCuello, M | |
| 700 | 1 | _aBalboa, J | |
| 700 | 1 | _aAcevedo, R | |
| 700 | 1 | _aZayas, C | |
| 700 | 1 | _aGil, D | |
| 700 | 1 | _aMora, N | |
| 700 | 1 | _aGonzález, D | |
| 700 | 1 | _aPérez, R | |
| 700 | 1 | _aGonzález, E | |
| 700 | 1 | _aBarberá, R | |
| 700 | 1 | _aFajardo, E M | |
| 700 | 1 | _aSierra, G | |
| 700 | 1 | _aSolís, R L | |
| 700 | 1 | _aCampa, C | |
| 773 | 0 |
_tScandinavian journal of immunology _gvol. 66 _gno. 2-3 _gp. 271-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-3083.2007.01981.x _zAvailable from publisher's website |
| 999 |
_c17170313 _d17170313 |
||